# Akebia Therapeutics Inc. (AKBA)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $230M  
**Price:** $0.89 (+2.51%)

> Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients impacted by kidney disease. Its lead product, Vafseo (vadadustat), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for treating anemia due to chronic kidney disease in adults on dialysis. The company also maintains a pipeline targeting rare kidney diseases, including praliciguat, an sGC stimulator in Phase 2 for biopsy-confirmed focal segmental glomerulosclerosis, and AKB-097, a tissue-targeted C3d-Factor H fusion protein complement inhibitor planned for Phase 2 basket studies across complement-mediated conditions such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional candidates like AKB-9090 address acute kidney injury associated with cardiac surgery. Akebia Therapeutics Inc. supports its portfolio through licensing agreements, such as for Vafseo in Europe, and engages in post-marketing studies to expand clinical understanding and patient access in the dialysis community. Headquartered in Cambridge, Massachusetts, the company plays a key role in addressing unmet needs in the nephrology sector with innovative oral therapies and targeted pipeline advancements.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $236M | $197M | $23M | -$5M | — |
| 2024 | $160M | $97M | -$50M | -$69M | — |
| 2023 | $195M | $120M | -$46M | -$52M | — |
| 2022 | $292M | $207M | -$81M | -$94M | — |
| 2021 | $212M | $61M | -$265M | -$282M | — |
| 2020 | $295M | -$2M | -$378M | -$385M | — |
| 2019 | $335M | $190M | -$286M | -$280M | — |
| 2018 | $208M | $200M | -$178M | -$144M | — |
| 2017 | $181M | — | -$77M | -$74M | — |
| 2016 | $2M | — | -$136M | -$136M | — |
| 2015 | — | — | -$62M | -$61M | — |
| 2014 | — | — | -$38M | -$37M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $377M | $344M | $33M | $185M | $48M |
| 2024 | $221M | $270M | -$49M | $52M | $39M |
| 2023 | $242M | $272M | -$31M | $43M | $35M |
| 2022 | $356M | $351M | $5M | $90M | $66M |
| 2021 | $529M | $455M | $74M | $150M | $98M |
| 2020 | $644M | $397M | $244M | $229M | $96M |
| 2019 | $771M | $376M | $393M | $147M | $76M |
| 2018 | $997M | $361M | $636M | $105M | — |
| 2017 | $364M | $242M | $123M | $70M | — |
| 2016 | $300M | $232M | $68M | $187M | — |
| 2015 | $143M | $12M | $131M | $50M | — |
| 2014 | $111M | $7M | $104M | $33M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $68M | $291,000 | $68M |
| 2024 | -$41M | $33,000 | -$41M |
| 2023 | -$23M | — | -$23M |
| 2022 | -$73M | $114,000 | -$73M |
| 2021 | -$253M | $59,000 | -$253M |
| 2020 | -$110M | $317,000 | -$111M |
| 2019 | -$257M | $7M | -$264M |
| 2018 | -$97M | $2M | -$99M |
| 2017 | -$56M | $2M | -$58M |
| 2016 | $58M | $3M | $55M |

Source: [CompaniesByCap](https://companiesbycap.com/company/AKBA)